Mandate

Vinge has advised Bilia in connection with the issuance and repurchase of bonds

Vinge has advised Bilia AB (publ) in connection with the issue of new senior and non subordinated bonds with a framework amount of SEK 1 500 000 000 as well as the repurchase of SEK 500 000 000 of a previously issued senior and non subordinated bond with a maturity date in 2021.

Initially, a bond in the amount of SEK 800 000 000 was issued, of which SEK 500 000 000 will be used for the repurchase of the previously issued bond and the remaining amount for repayment of bank loans as well as part financing of Bilia’s acquisitions in Belgium. 

The newly issued bonds have a term of 5 years and are subject to a variable interest of STIBOR 3M + 1.40%. 

Vinge’s team primarily consisted of Anders Strid, Lina André and Henrik Wastenson (tax).
 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025